RxDoctor Payments Data

Jimmy Lott, MD

Clinical Cardiac Electrophysiology · Jackson, MSNPI 1548206717

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $10,573 of the $16,231 with a category attached, or 65.1%. 26 manufacturers reported payments, led by Medtronic at 56.0% of the total. Reporting peaked in 2019 at $5,282 and has fallen 65.9% since, to $1,802 in 2025.

$16,231in general payments, 2019–2025

Across 242 payments — averaging $67.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Abbott$5K
  • Novartis$1K
  • Amgen$158
  • Impulse Dynamics (USA) Inc.$149
  • Boehringer Ingelheim$147
  • plus $763 from 20 others

What the payments were for

  • Travel & lodging$10,57365%
  • Food & beverage$5,53634%
  • Education$1211%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$398,557
Medicare patients
1,317
Services billed
8,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban431$298,470
EntrestoSacubitril/Valsartan99$90,689
XareltoRivaroxaban98$67,101
Repatha SureclickEvolocumab21$21,287
FarxigaDapagliflozin Propanediol19$20,247
JardianceEmpagliflozin18$13,385
Flecainide Acetate104$4,036
Metoprolol Succinate277$3,319
Dofetilide30$2,663
Amiodarone Hcl316$2,539
Digoxin109$1,824
Carvedilol145$1,087
Losartan Potassium106$935
Diltiazem 24hr ErDiltiazem Hcl23$784
Ondansetron OdtOndansetron72$693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$31$298,470431 claims
NovartisEntresto$1,225$90,68999 claims
Johnson & JohnsonXarelto$107$67,10198 claims
AstraZenecaFarxiga$27$20,24719 claims
Boehringer IngelheimJardiance$147$13,38518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other clinical cardiac electrophysiology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →